Literature DB >> 31260789

Optimal two-stage designs for exploratory basket trials.

Heng Zhou1, Fang Liu2, Cai Wu2, Eric H Rubin3, Vincent L Giranda3, Cong Chen2.   

Abstract

The primary goal of an exploratory oncology clinical trial is to identify an effective drug for further development. To account for tumor indication selection error, multiple tumor indications are often selected for simultaneous testing in a basket trial. In this article, we propose optimal and minimax two-stage basket trial designs for exploratory clinical trials. Inactive tumor indications are pruned in stage 1 and the active tumor indications are pooled at end of stage 2 to assess overall effectiveness of the test drug. The proposed designs explicitly control the type I and type II error rates with closed-form sample size formula. They can be viewed as a natural extension of Simon's optimal and minimax two-stage designs for single arm trials to multi-arm basket trials. A simulation study shows that the proposed design method has desirable operating characteristics as compared to other commonly used design methods for exploratory basket trials.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Efficacy screening; Immunotherapy; Master protocol; Trial optimization

Year:  2019        PMID: 31260789     DOI: 10.1016/j.cct.2019.06.021

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  2 in total

1.  The use of local and nonlocal priors in Bayesian test-based monitoring for single-arm phase II clinical trials.

Authors:  Yanhong Zhou; Ruitao Lin; J Jack Lee
Journal:  Pharm Stat       Date:  2021-05-19       Impact factor: 1.234

Review 2.  Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.

Authors:  Chengxing Cindy Lu; Xiaoyun Nicole Li; Kristine Broglio; Paul Bycott; Qi Jiang; Xiaoming Li; Anna McGlothlin; Hong Tian; Jingjing Ye
Journal:  Ther Innov Regul Sci       Date:  2021-06-23       Impact factor: 1.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.